

CORRECTIONS

In the Letter to Editor entitled "Altered metabolism of prostaglandin E2 in asthma patients with aspirin hypersensitivity" published in the July-August 2013 issue (Mastalerz L, Kumik J, Kasperkiewicz H, Kaszuba M, et al. Altered metabolism of prostaglandin E2 in asthma patients with aspirin hypersensitivity. *Pol Arch Med Wewn.* 2013; 123 (7-8): 423-424), grant No. in the Acknowledgments section should read N N402 373838 rather than K/PBW/0000552.

The article is correct at www.pamw.pl.

In the Original Article entitled "Studies of hepatocyte growth factor in bronchoalveolar lavage fluid in chronic interstitial lung diseases" published in the April 2014 issue (Przybylski G, Chorostowska-Wynimko J, Dyczek A, et al. *Pol Arch Med Wewn.* 2015; 125 (4): 260-271), Table 1 on pages 262-263 was not displayed correctly. The correct table can be found below.

The article is correct at www.pamw.pl.

TABLE 1 Demographic and clinical data of patients and control subjects

Group	PS			IPF		
	NS	S	treated ^a	NS	S	treated ^a
n	24	21	7	10	8	5
M/F	10/14	13/8	2/5	6/4	6/2	4/1
age, y ^b	43.7 ± 12.9 (25–75)	36.2 ± 10.9 (23–64)	50.1 ± 8.7 (38–66)	61.6 ± 11.1 (40–75)	59.9 ± 13.8 (33–75)	49 ± 7.9 (44–57) ^c
VC predicted, % ^b	101.4 ± 19.1 (58–133)	93.6 ± 18.3 (50–114)	101.7 ± 10.2 (86–110)	82.5 ± 23.7 (44–93)	94.4 ± 29.7 (44.1–113.9)	81 ± 9.9 (44.1–113.9)
DL _{CO} predicted, % ^b	88.1 ± 25.7 (55–141)	73.2 ± 16.9 (57–102)	86 ± 18.4 (62–113)	59.8 ± 22.6 (33–63)	45.4 ± 13.2 (21.8–55.7)	69.5 ± 7.6 (21.8–55.7)
disease duration, mo	8 ± 4.1 (3–15)	6.5 ± 2.2 (4–7)	11.5 ± 5.8 (8–14)	16 ± 9.9 (11–26)	14 ± 7.8 (11–22)	14.5 ± 6.3 (10–18)
pack-years of smoking, y		18 ± 9.1 (5–60)			42.5 ± 15.7 (7–58) ^c	

Nonsmokers and smokers were compared with respective controls, and corticosteroid-treated patients with nonsmoking, corticosteroid-naïve counterparts. Data are presented as median ± standard error of the mean (range).

a only nonsmoking patients were considered

b data are presented as mean ± standard deviation (range)

c $P < 0.05$ (Mann–Whitney test; exceptionally, t test for age was used)

Abbreviations: BOOP, bronchiolitis obliterans organizing pneumonia; DL_{CO}, diffusing capacity of the lungs for carbon monoxide; EAA, exogenous allergic alveolitis; EP, eosinophilic pneumonia; F, female; IPF, idiopathic pulmonary fibrosis; M, male; NS, nonsmokers; NSIP, nonspecific interstitial pneumonia; PS, pulmonary sarcoidosis; S, smokers; VC, vital capacity

NSIP		EAA	B00P	EP	Controls	
NS	treated ^a	NS	NS	NS	NS	S
9	5	6	8	6	7	6
2/7	0/5	3/3	6/2	3/3	2/5	4/2
59.2 ± 7.0 (51–69)	51.0 ± 9.9 (38–61)	48.1 ± 12.2 (35–72)	59.6 ± 5.2 (52–67) ^c	48.0 ± 18.3 (22–77)	46.4 ± 12.9 (26–66)	43.4 ± 13.4 (25–67)
82.7 ± 14.6 (65.0–104.0)	76.6 ± 29.6 (48.0–120.0)	81 ± 18.3 (71.0–105.0)	103 ± 15.7 (78.1–122.0)	79.5 ± 20.3 (50.8–102.0)		
62.3 ± 20.5 (40–97)	64.2 ± 11.1 (52–77)	61.1 ± 17.4 (44–88)	72.9 ± 9.7 (58–90)	74.9 ± 25.2 (52–127)		
20.5 ± 8.1 (16–26)	18.5 ± 5.2 (18–24)	36.5 ± 27.9 (6–432)	5.5 ± 2.3 (1–11)	20.5 ± 7.1 (3–15)		
						23.5 ± 7.2 (10.5–48)